Article Information
History
- April 1, 2022.
Article Versions
- Version 1 (March 6, 2022 - 10:07).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Masaharu Shinkai1,
- Takuhiro Sonoyama2,
- Akari Kamitani2,
- Risa Shibata2,
- Naomi Seki3,
- Shinya Omoto3,
- Masahiro Shinoda1,
- Takashi Sato1,
- Naoki Ishii4,
- Kenji Igarashi2 and
- Mari Ariyasu2,*
- 1Department of Respiratory Medicine, Tokyo Shinagawa Hospital, 6-3-22 Higashioi, Shinagawa-ku, Tokyo 140-8522, Japan
- 2Shionogi & Co., Ltd., Drug Development and Regulatory Science Division 8F, Nissay Yodoyabashi East Bldg., 3-3-13, Imabashi, Chuo-ku, Osaka 541-0042, Japan
- 3Shionogi & Co., Ltd., Pharmaceutical Research Division 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan
- 4Department of Gastroenterology, Tokyo Shinagawa Hospital, 6-3-22 Higashioi, Shinagawa-ku, Tokyo 140-8522, Japan
- ↵*Corresponding author:
Mari Ariyasu, 8F, Nissay Yodoyabashi East Bldg., 3-3-13, Imabashi, Chuo-ku, Osaka 541-0042, Japan, Phone: +81-6-6209-6962, Fax: +81-6-6209-8047, Email: mari.tatsuno{at}shionogi.co.jp
Posted April 01, 2022.
Immunogenicity and Safety of Booster Dose of S-268019-b or Tozinameran in Japanese Participants: An Interim Report of Phase 2/3, Randomized, Observer-Blinded, Noninferiority Study
